Sophiris shares rally on promising cancer treatment study

Sophiris Bio Inc. shares surged in the extended session Thursday after the tiny biotech's prostate cancer treatment showed promising results in a mid-stage clinical study. Sophiris shares rallied 74% to $2.04 on heavy volume after hours. The company said its treatment topsalysin showed an ability to destroy tumor cells in nine out of the 18 prostate cancer patients treated in a clinical study. "These promising early results open up the possibility of treating early prostate cancer by the simple administration of an injection into the prostate - something that could be done in an office setting," said Mark Emberton, an investigator on the study, in a statement.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.